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Italy (8). Reported prevalence ranges from 1.56 
observed in Sardinia (9) to 5.4 in Reggio Emilia 
(10) per 100,000 population. There is currently 
limited updated data on ALS frequency in southern 
Italy and in Sicily in particular, to offer the possibil-
ity of geographical comparison. We performed a 
survey in Sicily, which aimed to clarify the epide-
miological and clinical features of ALS and to com-
pare these data with those from other studies 
previously performed. 
 Methods 
 This study was conducted in Sicily, an island in 
southern Italy with nine administrative districts, 
 Introduction 
 Amyotrophic lateral sclerosis (ALS) is a neurode-
generative disorder with an incidence range between 
1.5 and 2.5 cases per 100,000 person-years (1). The 
mean survival time from onset of symptoms is 
approximately two years (1). Incidence based studies 
are expensive, and mortality studies have been used 
to obtain indirect estimates of ALS frequency (2  4). 
More recently, several studies have suggested that 
the validity of this methodology is questionable and 
several pitfalls may challenge the accuracy of offi cial 
statistics data (5,6). Previous surveys performed in 
Italy indicated mean annual incidence rates ranging 
from 2.5 in Piedmont and Valle d ’ Aosta region, in 
northern Italy (7), to 1.6 in Apulia region, in southern 
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 Our objective was to investigate incidence of amyotrophic lateral sclerosis (ALS) in Sicily, southern Italy, by means of a 
population based study. We included people with ALS resident in fi ve Sicilian provinces, whose onset occurred in the 
two-year period 2005  2006 (population at 31 December 2006: 3,481,096 inhabitants). A multisource case-fi nding pro-
cedure was adopted and patients were classifi ed as affected by ALS according to revised El Escorial criteria. During the 
two-year surveillance period, 97 patients meeting eligibility criteria included 57 males (58.8%) and 40 females (41.2%). 
Crude annual incidence rate was 1.4/100,000 person years (95% CI 1.33  1.47). The incidence rate was higher in males 
(1.71/100,000; CI 1.61  1.81) than in females (1.11/100,000; CI 1.01  1.21). Standardized incidence rate for the total 
population in the 45  74-years-old age group was 3.22 (CI 3.11  3.33). Prevalence rate was 6.0/100,000 (CI 5.97  6.03), 
higher in males (7.1/100,000; CI 7.02  7.18) than females (4.9/100,000; CI 4.86  4.94). In conclusion, ALS rates observed 
in the present study are higher in males than females, with a peak of incidence at 70 years of age in both genders. These 
fi ndings are consistent with those of other population based European studies. 
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called provinces. The area covers 25,710 square 
kilometres. The population of the study area was 
5,016,861 based on the Italian Statistics Bureau 
(ISTAT) data for the year 2006. In Sicily there are 
35 neurological departments and three referral cen-
tres for ALS, located at the neurological departments 
of the university hospitals of Palermo, Catania and 
Messina. We studied ALS in fi ve provinces (Agri-
gento, Caltanissetta, Catania, Palermo, Trapani), 
having previously ascertained that there was an ade-
quate participation rate from physicians and from 
neurological departments in these provinces. The 
population of the fi ve provinces considered was 
3,481,096 inhabitants on 31 December 2006. The 
primary sources we targeted included neurological 
departments located in the study area and hospital 
discharge diagnosis data bank (HDDB). The search 
code used for diagnosis of ALS was 335.2 (Interna-
tional Classifi cation of Disease, 10th revision). The 
regional registry for riluzole prescriptions was also 
used to trace patients who were subsequently inter-
viewed and examined personally. Standardized 
face-to-face questionnaires with clinical informa-
tion were used for this purpose. All of the forms 
were reviewed by neurologists expert in the fi eld, 
who confi rmed the diagnoses and decided for 
patients ’ inclusion. ALS diagnoses were based on 
the revised version of the El Escorial criteria (11). 
These criteria distinguish four levels of diagnostic 
certainty: defi nite, probable, probable laboratory 
supported, and possible ALS. Cases with progres-
sive muscular atrophy (PMA), primary lateral scle-
rosis (PLS), and progressive bulbar palsy (PBP) 
were included in the study and were reclassifi ed 
according to the El Escorial criteria. We calculated 
crude, and age- and gender-specifi c incidence curves 
for patients whose onset occurred in the two-year 
period 2005  2006 (population at 31 December 
2006: 3,481,096 inhabitants). Confi dence limits 
(95% CI) for incidence rates were calculated assum-
ing a normal distribution. The study is retrospective 
because case fi nding procedure was performed by 
analyses of all charts retrieved at the sources used 
for the study. All people who experienced their fi rst 
symptoms during the study period were included in 
the incident cohort; those who died were not con-
sidered as prevalent cases unless death occurred 
before prevalence day. Comparison with other stud-
ies was possible for the age interval between 45 and 
74 years. Standardized rates were also calculated 
using the direct method for this age group, with the 
1990 U.S. population as a standard, to allow com-
parisons with previous studies (12). Since some 
underestimation was possible due to the methodol-
ogy used, we also calculated completeness of the 
case-fi nding procedure and incidence rates accord-
ing to the capture-recapture methodology by match-
ing the records of hospital admission, the registries 
of ALS centres in Sicily, and the riluzole prescrip-
tion registries. 
 Results 
 During the two-year surveillance period, 97 patients 
meeting the eligibility criteria were included: 57 
males (58.8%) and 40 females (41.2%) with a male 
to female ratio of 1.4:1. Mean age at disease onset 
was 58.3 years (SD    14.6) and mean age at diag-
nosis was 59.5 years. There was a similar delay 
between males and females in the onset of symp-
toms and the diagnosis (mean 15.2 months for the 
whole cohort; 15.6 males, 14.5 females). Twelve 
patients were under 45 years of age (12.4%). No 
familial ALS cases were identifi ed in the incident 
cohort. There were three patients with ALS-Frontal 
Temporal Dementia (ALS-FTD; 3.1%), three with 
PLS (3.1%) and four with PMA (4.1%). Almost 
24% of patients had bulbar onset of symptoms and 
70% of individuals had spinal onset. One patient 
(0.9%) experienced respiratory symptoms at onset 
while in 4.5% the type of onset was of uncertain 
classifi cation. A higher rate of bulbar symptoms 
was noted among females (31.9%) than males 
(20.7%). Using the revised El Escorial diagnostic 
criteria, 69.4% of cases were classifi ed as defi nite 
or probable, 5.4% were classifi ed as laboratory sup-
ported, and 25.2% as possible (Figure 1). Crude 
 Figure 1. Proportion of ALS incident cases according to El 
Escorial criteria. 
 Figure 2. Crude and age- and gender-specifi c incidence rates 
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annual incidence rate for ALS at the end of the 
observation period (2005 – 2006) was 1.4/100,000 
person-years (95% CI 1.33  1.47). Incidence rate 
was higher in males (1.71; CI 1.61  1.81) than 
females (1.11; CI 1.01 – 1.21). This proportion of 
higher incidence in males remained similar at all 
age groups. There was some variability among the 
fi ve provinces but no signifi cant differences were 
detected. As illustrated in Figure 2, incidence 
showed a progressive increase up to age 75 years, 
and declined thereafter maintaining a similar trend 
in both genders with higher rates in males at all 
ages. Incidence rates of ALS in the fi ve provinces 
considered are shown in Table I. We compared inci-
dence rates in Sicily to those from previous studies 
with respect to the age range between 45 and 74 
years by adjusting all the rates to the U.S. 1990 
general population, as illustrated in Table II. 
Adjusted incidence rates for these age groups were 
3.22/100,000 person-years (95% CI 3.11  3.33) in 
both genders: 4.3 in males (CI 4.13  4.41) and 
2.27 in females (CI 2.11  2.43). We also calculated 
the prevalence rate of ALS on 31 December 2006. 
Crude prevalence was 6.0 per 100,000 population 
(CI 5.97 – 6.03): 7.1 in males (95% CI: 7.02 – 7.18), 
and 4.9 in females (CI: 4.86 – 4.94). By matching 
the three main sources of information according to 
the capture-recapture methodology, we estimated a 
rate of accuracy of our search strategy of 72.1%. 
Recalculating incidence rates according to these 
calculations would give an incidence rate of 1.95 
per 100,000 population for the whole population 
considered (95% CI 1.88 – 2.02) and of 2.46 per 
100,000 population for the population aged over 
18 years (CI 2.39 – 2.53). 
 Discussion 
 Our study, performed in a southern Mediterranean 
island, used a retrospective cohort design to ascer-
tain the incidence of ALS according to diagnostic 
criteria adopted by several previous studies (13  15). 
The observed incidence rates were higher for males 
compared to females and showed a similar progres-
sive increase up to 70 years of age in both genders, 
with a rapid decrease thereafter. Incidence rates 
observed in the present study are lower compared to 
those previously reported in Italy (1,7,8,13). This 
may be due at least in part to the retrospective nature 
of the study. To minimize a possible underestima-
tion we focused our study on the health districts of 
Sicily with high participation rates by physicians and 
neurologists, and where it was possible to confi rm 
each diagnosis by direct examination of patients and 
of clinical records. A previous report from a single 
Sicilian province has shown rates lower than expected 
and lower than those reported in other geographic 
areas (16). The reported annual incidence in that 
study was 0.44/100,000 inhabitants. It is likely that 
methodological differences may have infl uenced the 
results. At the time of the fi rst study, performed in 
the province of Palermo, there were no disease 
archives and little information available for patients, 
particularly for rare conditions. In 1994, the El 
Escorial criteria were published (11), and although 
these criteria did not introduce specifi c instrumental 
 Table I. Annual gender- and age-specifi c incidence rates of amyotrophic lateral sclerosis in Sicily, southern Italy. 
Males Females Both genders
Age (years) Population Cases Rate 95% CI Population Cases Rate 95% CI Population Cases Rate 95% CI
0  –  17 369,019.5 0 – – 350,100.5 0 – – 719,120 0 – –
18  –  24 161,532.5 1 0.31 0.03  –  0.65 157,547.5 0 – – 319,080 1 0.16 0.09  –  0.40
25  –  34 236,511 0 – – 252,273.5 3 0.59 0.33  –  0.86 488,784.5 3 0.31 0.11  –  0.50
35  –  44 250,587.5 2 0.40 0.13  –  0.67 267,026 4 0.75 0.49  –  1.01 517,613.5 6 0.58 0.39  –  0.77
45  –  54 212,902.5 11 2.58 2.32  –  2.84 229,575.5 5 1.09 0.82  –  1.36 442,478 16 1.81 1.62  –  2.00
55  –  64 178,182 16 4.49 4.25  –  4.73 195,566 10 2.56 2.29  –  2.83 373,748 26 3.48 3.30  –  3.66
65  –  74 148,850 20 6.72 6.51  –  6.92 178,552 13 3.64 3.38  –  3.90 327,402 33 5.04 4.87  –  5.21
75  –  84 89,539 7 3.91 3.55  –  4.27 129,894 4 1.54 1.19  –  1.89 219,433 11 2.51 2.25  –  2.76
85   19,923 0 38,158 1 1.31 0.65  –  1.97 58,081 1 0.86 0.31  –  1.41
Total 1,667,047 57 1.71 1.61  –  1.81 1,798,693 40 1.11 1.01  –  1.21 3,465,740 97 1.40 1.33  –  1.47
Incidence rate among individuals over 18 years of age was 1.77 for the total population (CI 1.69−1.85); 2.20 (CI 2.09−2.31) in males, 
and 1.38 (CI 1.27−1.49) in females.
 Table II. Standardized incidence rate in Sicily adjusted to the 1990 U.S.   population for 
the age groups 45  74 years. 
Years 2005  –2006 Observed incidence rate Adjusted incidence rate 95% CI * 
Total 3.28 3.22 3.11  –  3.33
Males 4.35 4.27 4.13  –  4.41
Females 2.31 2.27 2.11  –  2.43
*95% CI: 95% confi dence intervals for incidence rates standardized to the 1990 U.S. 
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tests, it is likely that their use may have infl uenced 
estimates of incidence. The availability of riluzole 
therapy has also raised the level of disease awareness 
among physicians and consequently, the opportunity 
for possible ALS patients to come to neurologists ’ 
attention. We included all four diagnostic levels of 
the revised version of El Escorial and included PLS 
and PMA in the calculation of the incidence and 
prevalence rates. These were classifi ed as possible cases 
and accounted for a quarter of the total of ALS diag-
noses. As has been previously noted, age-specifi c curves 
show a peak at about 70 years of age with a decline 
thereafter (17). This suggests the presence of environ-
mental factors acting during specifi c critical periods of 
life. An alternative explanation is the possible underes-
timation of disease symptoms among these older indi-
viduals. Standardized rates adjusted for the 45  74 
years age group as shown in Table II, make it easier to 
compare our results with those from previous studies 
performed in other geographic areas at different times 
(1,17,18). These comparisons give further strength to 
the fact that the observed rates refl ect the real distribu-
tion of ALS in Sicily showing incidences that are lower, 
but close to, those of previous reports in Italy. One 
possible explanation for the different rates observed in 
our population may relate to the different historical 
background of the Sicilian population that can be con-
sidered genetically admixed. A previous study has sug-
gested that genetic admixture could account for 
differential risks across populations for complex degen-
erative diseases such as ALS (19,20). However, we 
consider that a more probable explanation for the 
slightly lower incidence rates of ALS described in our 
study may be attributed to some underascertainment 
because of the retrospective data collection. 
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